Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Marrow sets out to challenge genetic medicines for severe blood diseases

Armed with $173 million in venture funding, the startup is developing what it’s positioning as a more accessible alternative to gene therapy and gene editing treatments for sickle cell and beta thalassemia.

We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.

Read the original at biopharmadive.com →

More in Health & Medicine

More from Tuesday 17 November →